Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
After 10 consecutive days of once-daily oral administration, no consistent or clinically relevant pattern of increase or decrease in semaglutide exposure was observed between individuals with varying degrees of renal function
Retatrutide is an investigational peptide currently undergoing clinical trials as a potential treatment for obesity and type 2 diabetes
Zepbound is approved for sleep apnea and Wegovy is approved for heart disease, but only in patients with obesity
Summary: The dosing schedule for retatrutide used in Phase 2 clinical trials involved once-weekly subcutaneous injections starting at a low dose and gradually escalating up to 12 mg, but retatrutide is not yet approved for use in the UK
B.KerrJ
Figure 21: Photograph of Professor Joel Habener, credit: Endocrine Society
